MONISTAT 3 Drug Patent Profile
✉ Email this page to a colleague
When do Monistat 3 patents expire, and when can generic versions of Monistat 3 launch?
Monistat 3 is a drug marketed by Medtech Products and is included in four NDAs.
The generic ingredient in MONISTAT 3 is miconazole nitrate. There are twenty-eight drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the miconazole nitrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Monistat 3
A generic version of MONISTAT 3 was approved as miconazole nitrate by ACTAVIS PHARMA on November 19th, 1993.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MONISTAT 3?
- What are the global sales for MONISTAT 3?
- What is Average Wholesale Price for MONISTAT 3?
Summary for MONISTAT 3
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,441 |
| What excipients (inactive ingredients) are in MONISTAT 3? | MONISTAT 3 excipients list |
| DailyMed Link: | MONISTAT 3 at DailyMed |
Recent Clinical Trials for MONISTAT 3
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Universidad Autonoma de San Luis Potosà | Phase 4 |
| Hospital Central "Dr. Ignacio Morones Prieto" | Phase 4 |
Pharmacology for MONISTAT 3
| Drug Class | Azole Antifungal |
US Patents and Regulatory Information for MONISTAT 3
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medtech Products | MONISTAT 3 | miconazole nitrate | CREAM;VAGINAL | 020827-001 | Mar 30, 1998 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Medtech Products | MONISTAT 3 COMBINATION PACK | miconazole nitrate | CREAM;TOPICAL, VAGINAL | 021261-003 | Jun 17, 2003 | OTC | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Medtech Products | MONISTAT 3 | miconazole nitrate | SUPPOSITORY;VAGINAL | 018888-001 | Aug 15, 1984 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MONISTAT 3
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Medtech Products | MONISTAT 3 | miconazole nitrate | SUPPOSITORY;VAGINAL | 018888-001 | Aug 15, 1984 | ⤷ Start Trial | ⤷ Start Trial |
| Medtech Products | MONISTAT 3 | miconazole nitrate | SUPPOSITORY;VAGINAL | 018888-001 | Aug 15, 1984 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MONISTAT 3
See the table below for patents covering MONISTAT 3 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| India | 139930 | PROCESS FOR THE PREPARATION OF IMIDAZOLE DERIVATIVES | ⤷ Start Trial |
| Yugoslavia | 212669 | ⤷ Start Trial | |
| Czechoslovakia | 184772 | METHOD FOR PRODUCING IMIDAZOLE DERIVATIVES | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch